Trade

with

Halozyme Therapeutics Inc
(NASDAQ: HALO)
AdChoices
9.15
-0.10
-1.08%
After Hours :
-
-
-

Open

9.19

Previous Close

9.25

Volume (Avg)

628.61k (1.30M)

Day's Range

9.10-9.46

52Wk Range

6.88-18.18

Market Cap.

1.16B

Dividend Rate ( Yield )

-

Beta

1.60

Shares Outstanding

125.31M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 54.80M

    • Net Income

    • -83.48M

    • Market Cap.

    • 1.16B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -142.87

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.60

    • Forward P/E

    • -25.13

    • Price/Sales

    • 18.45

    • Price/Book Value

    • 20.96

    • Price/Cash flow

    • -17.57

      • EBITDA

      • -78.98M

      • Return on Capital %

      • -58.11

      • Return on Equity %

      • -253.15

      • Return on Assets %

      • -58.11

      • Book Value/Share

      • 0.44

      • Shares Outstanding

      • 125.31M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 16.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.37

        • Cashflow Estimate

        • -0.29

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 27.20

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 44.28

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 73.38

            • 82.75

            • Pre-Tax Margin

            • -142.87

            • 39.38

            • Net Profit Margin

            • -142.87

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 95.20

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -226.40

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.79

              • 0.76

              • Current Ratio

              • 5.54

              • 2.92

              • Quick Ratio

              • 5.06

              • 2.35

              • Interest Coverage

              • -18.09

              • 38.02

              • Leverage Ratio

              • 3.29

              • 2.21

              • Book Value/Share

              • 0.44

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -12.76

                • 243.90

                • P/E Ratio 5-Year High

                • -25.33

                • 634.30

                • P/E Ratio 5-Year Low

                • -5.38

                • 124.82

                • Price/Sales Ratio

                • 18.21

                • 9.29

                • Price/Book Value

                • 20.75

                • 8.39

                • Price/Cash Flow Ratio

                • -17.57

                • 49.75

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -253.15

                        (-359.70)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -58.11

                        (-57.70)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -107.64

                        (-258.20)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 3.27

                      • 1.48

                      • Asset Turnover

                      • 0.41

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -80.43M
                      Operating Margin
                      -146.78
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -17.57
                      Ownership

                      Institutional Ownership

                      73.96%

                      Top 10 Institutions

                      50.93%

                      Mutual Fund Ownership

                      31.17%

                      Float

                      83.06%

                      5% / Insider Ownership

                      7.91%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Bb Biotech AG

                      •  

                        6,430,532

                      • 9.99

                      • 5.13

                      • Pictet-Biotech

                      •  

                        3,546,109

                      • 0.07

                      • 3.18

                      • First Eagle Fund of America

                      •  

                        3,141,080

                      • 0.00

                      • 2.51

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        2,796,723

                      • 0.00

                      • 2.23

                      • Vanguard Small Cap Index

                      •  

                        1,741,918

                      • 0.32

                      • 1.39

                      • SPDR® S&P Biotech ETF

                      •  

                        1,698,409

                      • -9.84

                      • 1.33

                      • Franklin Biotechnology Discovery

                      •  

                        1,661,973

                      • 5.96

                      • 1.34

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,630,147

                      • 0.00

                      • 1.30

                      • iShares Nasdaq Biotechnology

                      •  

                        1,628,834

                      • -0.24

                      • 1.28

                      • iShares Russell 2000 (AU)

                      •  

                        1,557,954

                      • -1.81

                      • 1.22

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Third Security, LLC

                      •  

                        19,816,162

                      • +0.13%

                      • 15.82

                      • Bellevue Asset Management AG

                      •  

                        6,430,532

                      • +9.99%

                      • 5.13

                      • BB Biotech AG

                      •  

                        6,271,564

                      • +9.14%

                      • 5.01

                      • Iridian Asset Management LLC

                      •  

                        6,199,685

                      • +91.81%

                      • 4.95

                      • Vanguard Group, Inc.

                      •  

                        6,155,526

                      • +0.06%

                      • 4.91

                      • Qvt Financial LP

                      •  

                        4,556,090

                      • +7.99%

                      • 3.64

                      • Sectoral Asset Management Inc

                      •  

                        4,389,682

                      • -18.03%

                      • 3.50

                      • BlackRock Fund Advisors

                      •  

                        3,755,627

                      • -5.13%

                      • 3.00

                      • Fidelity Management and Research Company

                      •  

                        3,207,340

                      • -39.20%

                      • 2.56

                      • State Street Corp

                      •  

                        3,018,348

                      • +1.64%

                      • 2.41

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Halozyme Therapeutics, Inc. was incorporated in November 2007. It is a biopharmaceutical company engaged in making molecules into medicines for patients in need. The Company’s research aims at extracellular matrix, an area outside th...moree cell that provides structural support in tissues and orchestrates many biological activities, including cell migration, signaling and survival. All its approved product and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid "HA" - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage, this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injecta...moreble biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. It refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as Enhanze™ technology. rHuPH20 is also the active ingredient in its first commercially approved product, Hylenex® recombinant. Additionally, the Company is expanding its scientific work in the extracellular matrix by developing other enzymes and agents that target its primary aspects, giving rise to new molecular entities that can be indicated in endocrinology, oncology and dermatology. It operates under one segment, which includes all activities related to the research, development and commercialization of human enzymes that either transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids or to alter abnormal tissue structures for clinical benefit. The Company’s proprietary program is engages in the formulation of rHuPH20 with prandial "mealtime" insulins for the treatment of diabetes mellitus. Company’s Enhanze™ technology is the platform for the delivery of proprietary small and large molecules. It has combined rHuPH20 with an analog insulin, e.g., insulin lispro (Humalog®), or Lispro-PH20, insulin aspart (Novolog®), or Aspart-PH20, and insulin glulisine (Apidra®), or each such combination, Analog-PH20, to accelerate their action. HTI-501, a recombinant human proteinase known as cathepsin L, is a lysosomal proteinase that acts by degrading collagen and is its first conditionally-active biologic. Collagen is an abundant protein in the body, particularly in connective tissue, and is present in high amounts in the extracellular matrix in the form of collagen fibers. The Company has engaged third parties to manufacture bulk rHuPH20 and its product Hylenex recombinant. Its patent portfolio includes 20 issued patents in the U.S., 57 issued patents in Europe and other countries in the world and some pending patent applications. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. "Roche", Pfizer Inc. "Pfizer", Baxter Healthcare Corporation "Baxter" and Intrexon Corporation "Intrexon" with two products approved for marketing in Europe, as well as others at different stages of development. The FDA and comparable regulatory agencies in foreign countries regulate extensively the manufacture and sale of the pharmaceutical products that it has developed or currently are developing.lessless

                      Key People

                      Dr. Helen Torley, MB.Ch.B.

                      CEO/Director/President

                      Kenneth J. Kelley

                      Chairman of the Board/Director

                      David A. Ramsay

                      CFO/Chief Accounting Officer/Vice President

                      Jean I. Liu

                      General Counsel/Secretary/Vice President

                      Dr. H. Michael Shepard, PhD

                      Chief Scientific Officer/Vice President

                      • Halozyme Therapeutics Inc

                      • 11388 Sorrento Valley Road

                      • San Diego, CA 92121

                      • USA.Map

                      • Phone: +1 858 794-8889

                      • Fax: +1 858 704-8311

                      • halozyme.com

                      Incorporated

                      2007

                      Employees

                      170

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: